An observational study in Post Partum Hemorrhage and Anemia of Pregnancy, sponsored by Inova Health Care Services. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Inova Health Care Services · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Postpartum Hemorrhage with a site in United States — 10 open to participants now, 12 under way, 3 of them phase 3. Postpartum Hemorrhage · United States.
Among the 65 studies in Postpartum Hemorrhage with a site in United States, this one is the 7th largest by planned enrollment of the 18 observational ones that give a count, is one of 7 that started in 2025, is one of 18 observational ones, reaches primary completion later than 9 of the 11 other live ones, and was the 54th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →10 of the 65 studies in Postpartum Hemorrhage with a site in United States are open now. Recruiting first, the newest first:
ResQ Medical Ltd · Sites in United States, Israel
Ages 18+ · Women only
Endeavor Health · Sites in United States
Ages 17+ · Women only · Healthy volunteers
Stony Brook University · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Stanford University · Sites in United States
Ages 18–50 · Women only
Holly Ende · Sites in United States
Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 7 · Phase 4 9
First in 2002; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 169 across 96 observational studies indexed under Postpartum Hemorrhage.
Median enrollment 65 across the 46 interventional studies, 108 across the 18 observational. Of the 50 that completed or were terminated, 24 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 65 have an industry lead sponsor. The 10 most frequent:
Inova Health Care Services is the lead sponsor of 86 studies on the registry; 20 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
Inova Health Care Services has 2 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
8 of the studies in Postpartum Hemorrhage with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06646653Phase 3ResQ Medical LtdEVE TRIAL , ALMA SYSTAM | 2027-01 |
| NCT05245227Phase 3Stony Brook UniversityDouble Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage | 2027-01-01 |
| NCT04146376University of WashingtonVon Willebrand Factor in Pregnancy (VIP) Study | 2026-12 |
| NCT05488457Stanford UniversityOxytocin Pharmacokinetics and Pharmacodynamics | 2026-12-30 |
| NCT06898034Endeavor HealthPostpartum Ultrasound Evaluation to Assess Risk of Hemorrhage | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Postpartum Hemorrhage with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The project is a prospective observational study aimed to assess and to validate the use of point-of-care hemoglobin testing in pregnancy. Point-of-care hemoglobin testing has the potential to (1) increase access to hemoglobin monitoring in pregnancy in low resource settings, (2) increase availability of hemoglobin monitoring in anemic patients, and (3) provide immediate results for real-time patient counseling and intervention. However, to date, point-of-care hemoglobin testing devices have not yet been studied for use in an ambulatory obstetric population. The Masimo device is a Root Radical 7 Pulse CO-Oximeter, manufactured by Masimo, Inc. This device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value. The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement, and The Rubby is a mobile application based platform that uses a photo of the participants nailbed to estimate hemoglobin values. Participants in this study will be approached at the Obstetrics and Gynecology clinics at George Washington Medical Faculty Associates. Point-of-care hemoglobin measurements will be assessed using the non-invasive Masimo device along with minimally-invasive hemoglobin HemoCue® Hb 801 device and compared to traditional venipuncture hemoglobin testing.
This will be a prospective, observational study for which aim to recruit 200 patients over the study period. Patients will be approached at one of the MFA Obstetrics and Gynecology clinics. Once consented, they will be approached at least two time-points during their antenatal care as below:
May need to get more Hb time-points readings (up to five readings) if the patient will be diagnosed with anemia at any of the previously mentioned visits or will be scheduled to have more blood draws during the prenatal care period. At each time-point visit, we plan to talk with the provider of the patient about the study. Then the study protocol and the recruitment process with the patient will be discussed. If the patient consents, the researchers will coordinate with the lab personnel the exact time of the routinely ordered blood draw (as a part of the subject's antenatal care) to determine the appropriate time to get the Hb readings using the devices (preferrably, right before the venipuncture). To obtain the readings, a study research coordinator will apply a disposable probe (Rainbow R1 25 adult adhesive sensor) connected to a Radical-7 co-oximeter sensor on the ring finger of the same arm of the venipuncture, shielded by an opaque covering to eliminate intereference from ambient light to obtain the SpHb reading. In addition, during in the same setting, we will ask for a finger prick capillary sample to get the Hemocue Hb reading as well (the same side will be used). Both readings will be tabulated in a case report form and the standard lab hemoglobin reading will be added to them once received. This is how it will validate the performance of the Masimo and the Hemocue devices with the routine lab test results. Additionally, the researchers will collect demographics, procedure-specific and some antenatal-care variables including vitals, gestational age and the exact date and time of the records at each time point visit, using a well-structured case report form.
Pregnant women ages 18-50 years old
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Masimo device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value.
The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement.
Validity of each POC device to detect anemia
Sensitivity, specificity, and positive and negative predictive values for each POC device to detect anemia (Hgb \< 11mg/dL) or severe anemia (Hgb \< 9mg/dL).
Time frame: Within 6 hours of CBC draw
To determine if Point of Care Hemoglobin testing correlates to clinical laboratory results.
Verify the correlation between point-of-care hemoglobin/ferritin values and the reference laboratory hemoglobin from a CBC (complete blood count) and clinical ferritin test. This aim will help us determine the suitability of the selected testing methods.
Time frame: 24 - 48 hours to get all test results
Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.
Of 38 non-industry observational studies under Postpartum Hemorrhage, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 21 months is below that.
Counting every sponsor, half of 42 studies reached it within 21 months; a quarter within 9 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Sep 2026 → Sep 2027 and completion Dec 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inova Health Care Services